TY  - INPR
UR  - https://doi.org/10.1007/s40259-023-00577-7
PB  - Springer Science and Business Media LLC
ID  - discovery10165469
N2  - Transthyretin (TTR) is a tetrameric protein synthesized primarily by the liver. TTR can misfold into pathogenic ATTR amyloid fibrils that deposit in the nerves and heart, causing a progressive and debilitating polyneuropathy (PN) and life-threatening cardiomyopathy (CM). Therapeutic strategies, which are aimed at reducing ongoing ATTR amyloid fibrillogenesis, include stabilization of the circulating TTR tetramer or reduction of TTR synthesis. Small interfering RNA (siRNA) or antisense oligonucleotide (ASO) drugs are highly effective at disrupting the complementary mRNA and inhibiting TTR synthesis. Since their development, patisiran (siRNA), vutrisiran (siRNA) and inotersen (ASO) have all been licensed for treatment of ATTR-PN, and early data suggest these drugs may have efficacy in treating ATTR-CM. An ongoing phase 3 clinical trial will evaluate the efficacy of eplontersen (ASO) in the treatment of both ATTR-PN and ATTR-CM, and a recent phase 1 trial demonstrated the safety of novel in vivo CRISPR-Cas9 gene-editing therapy in patients with ATTR amyloidosis. Recent results from trials of gene silencer and gene-editing therapies suggest these novel therapeutic agents have the potential to substantially alter the landscape of treatment for ATTR amyloidosis. Their success has already changed the perception of ATTR amyloidosis from a universally progressive and fatal disease to one that is treatable through availability of highly specific and effective disease-modifying therapies. However, important questions remain including long-term safety of these drugs, potential for off-target gene editing, and how best to monitor the cardiac response to treatment.Kindly check and confirm the processed running title.This is correct.
A1  - Ioannou, Adam
A1  - Fontana, Marianna
A1  - Gillmore, Julian D
JF  - BioDrugs
AV  - public
Y1  - 2023/02/16/
TI  - RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis
N1  - This article is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License, which permits
any non-commercial use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The
images or other third party material in this article are included in the
article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy
of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
ER  -